INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio (NASDAQ: INMB) reported exploratory chi-separation MRI results from its MINDFuL Phase 2 Alzheimer’s trial of XPro1595 (XPro). According to the company, after 24 weeks the full mITT group (n=200) showed a significant myelin treatment effect (p=0.0028; d=0.46), strengthening in inflammation-enriched patients (n=100; p=0.0098; d=0.59). The company plans to present full data at AAIC 2026.
How this was made
The 30-second read
Why it matters
The company highlights statistically significant myelin-related chi-separation MRI effects at 24 weeks, with stronger results in inflammation-enriched patients, and links this to FDA Fast Track and End-of-Phase 2 alignment for a Phase 2b/3 registrational pathway.
Market read
A fresh, statistically significant biomarker/target-engagement datapoint for INMB’s Alzheimer’s program, strengthening in inflammation-enriched patients and reinforcing the registrational strategy.
What to watch
Key uncertainties remain around translation from biomarker improvement to CDR-SB/EMACC outcomes in the Phase 2b/3 adaptive design; also ARIA absence is supportive but not a substitute for efficacy.
Background
INmune Bio’s XPro1595 (XPro) is an inflammatory cytokine modulator targeting soluble TNF; MINDFuL is a Phase 2 trial in early Alzheimer’s (MCI and mild dementia).
Ticker impact
INmune Bio reported statistically significant MINDFuL Phase 2 chi-separation MRI treatment effects on myelin, strengthening in inflammation-enriched patients.
Near-term upside bias possible on biotech sentiment, but magnitude likely capped until clinical efficacy endpoints are reported.
The release is a new, specific datapoint (p-values/effect sizes) tied to a mechanistic biomarker and regulatory pathway (End-of-Phase 2 alignment, Fast Track), which typically improves perceived probability of success; however, it is still exploratory MRI biomarker data rather than definitive clinical outcomes.
Market effects
Reinforces the anti-neuroinflammation thesis and the use of advanced white-matter MRI biomarkers as target-engagement tools in Alzheimer’s trials.
No explicit regional demand/supply impacts; primarily US biotech sentiment.
AAIC 2026 presentation planned in London may extend international attention to similar CNS inflammation programs.
Counterpoint
Chi-separation MRI is a target-engagement/biomarker endpoint; without clinical efficacy readouts, the market may discount the signal or treat it as supportive rather than decisive.
Key entities
- companyINmune Bio Inc.
Subject of the press release reporting new Phase 2 MINDFuL chi-separation MRI biomarker results for XPro1595.
- drugXPro1595 (XPro)
Investigational anti-neuroinflammatory cytokine modulator; reported myelin treatment effects via chi-separation MRI.
- clinical_programMINDFuL Phase 2 trial
Early Alzheimer’s Phase 2 study whose exploratory MRI analyses produced the new statistically significant biomarker findings.
- regulatoryFDA Fast Track
Regulatory designation referenced as supporting the planned Phase 2b/3 registrational architecture.
- conferenceAAIC 2026
Planned venue (July 12-15, 2026) to present the complete chi-separation dataset and additional MRI endpoints.
